UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Smoking on the Pharmacokinetics of Erlotinib

Clinical cancer research, 2006-04, Vol.12 (7), p.2166-2171

2006

Volltextzugriff (PDF)

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers

Drug metabolism and disposition, 2006-03, Vol.34 (3), p.420-426

2006

Volltextzugriff (PDF)

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Cancer chemotherapy and pharmacology, 2014-03, Vol.73 (3), p.613-621

2014

Volltextzugriff (PDF)

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4921-4927

2008

Volltextzugriff (PDF)

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

European journal of clinical pharmacology, 2008-01, Vol.64 (1), p.31-41

2008

Volltextzugriff (PDF)

Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury

Kidney international reports, 2017-09, Vol.2 (5), p.836-843

2017

Volltextzugriff (PDF)

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.282-290

2006

Volltextzugriff (PDF)

Blanket Ban

2022

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers

Clinical cancer research, 2004-11, Vol.10 (22), p.7547-7554

2004

Volltextzugriff (PDF)

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1859-1866

2005

Volltextzugriff (PDF)

Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine

Anti-cancer drugs, 2015-06, Vol.26 (5), p.565-572

2015

Volltextzugriff (PDF)

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-12, Vol.12 (24), p.7406-7413

2006

Volltextzugriff (PDF)

Pharmacokinetics of Tenofovir in Breast Milk of Lactating Rhesus Macaques

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.2093-2094

2005

Volltextzugriff (PDF)

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Neuro-oncology (Charlottesville, Va.), 2010-12, Vol.12 (12), p.1300-1310

2010

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1222-1231

Kehrer, D. F.S.

2002

Volltextzugriff (PDF)

Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan

Clinical cancer research, 2000-07, Vol.6 (7), p.2903-2912

2000

Volltextzugriff (PDF)

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer

Clinical pharmacology and therapeutics, 2006-08, Vol.80 (2), p.136-145

2006

Volltextzugriff (PDF)

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer

Anti-cancer drugs, 2014-08, Vol.25 (7), p.832-840

2014

Volltextzugriff (PDF)

Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Antimicrobial Agents and Chemotherapy, 2004-05, Vol.48 (5), p.1469-1487

2004

Volltextzugriff (PDF)

Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20(S)-Camptothecin, a Photodegradant of Lurtotecan

Clinical cancer research, 2002-03, Vol.8 (3), p.856-862

2002

Volltextzugriff (PDF)

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

Cancer chemotherapy and pharmacology, 2007-07, Vol.60 (2), p.295-303

2007

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of a low‐clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

Cancer, 2004-04, Vol.100 (7), p.1449-1458

2004

Volltextzugriff (PDF)

Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach

AAPS PharmSciTech, 2004-01, Vol.5 (1), p.151-158

2004

Volltextzugriff (PDF)

Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Antimicrobial agents and chemotherapy, 2004-06, Vol.48 (6), p.2346-2346

2004

Volltextzugriff (PDF)

Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection

Journal of chromatography. B, Biomedical applications, 1995-03, Vol.665 (1), p.171-181

1995

Volltextzugriff (PDF)

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(179)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(204)
Portugiesisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effects of Smoking on the Pharmacokinetics of Erlotinib

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Blanket Ban

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group

Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Pharmacokinetics of Tenofovir in Breast Milk of Lactating Rhesus Macaques

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity

Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer

Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20(S)-Camptothecin, a Photodegradant of Lurtotecan

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

Phase I and pharmacokinetic study of a low‐clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach

Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection

Suchergebnisse filtern